Canaccord lowered the firm’s price target on Akoya Biosciences (AKYA) to $1.80 from $3.50 and keeps a Hold rating on the shares. The firm said its target decrease reflects multiple headwinds including tariffs, funding uncertainty, recession fears, and China.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- Akoya expands portfolio with new ADC breast cancer assay at AACR 2025
- Akoya Biosciences, Enable Medicine launch single-cell spatial proteomics atlas
- Akoya Biosciences, STCC partner on SUPER study for cancer immunophenotyping
- Akoya Biosciences price target lowered to $1.65 from $2.40 at Piper Sandler
- Akoya Biosciences, Team SAMBAI announce selection of PhenoCycler-Fusion